The treatment potential in preventive cardiology

Atheroscler Suppl. 2001 Feb;2(1):3-8. doi: 10.1016/s1567-5688(00)00003-9.

Abstract

The Joint European Societies--European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension--1998 recommendations on prevention of coronary heart disease (CHD) in clinical practice set priorities and goals. The top priority is patients with established CHD, or other atherosclerotic disease, because they are already under the care of cardiologists and are at high risk of further morbidity and mortality. The lifestyle goals are to stop smoking, make healthy food choices and be active physically. The risk factor goals are a BP < 140/90 mmHg, total cholesterol < 5.0 mmol/l (190 mg/dl) and LDL-cholesterol < 3.0 mmol/l (115 mg/dl). The appropriate use of prophylactic drug therapies--aspirin, beta-blockers, ACE inhibitors, lipid modification therapies and anticoagulants--is also a recommended goal. The final goal is to screen relatives of patients with premature CHD (men < 55 years and women < 65 years). Surveys of clinical practice such as EUROASPIRE (European Action on Secondary Prevention) have shown risk can be further reduced in patients with established CHD because many are not achieving these lifestyle and risk factor goals. So there is considerable potential to raise the standard of preventive care for coronary patients through more effective lifestyle intervention and the use of drug therapies with proven efficacy. For the patient, this will mean a longer life with better quality.

Publication types

  • Review

MeSH terms

  • Blood Pressure / physiology
  • Cholesterol / blood
  • Cholesterol, LDL / blood
  • Coronary Disease / drug therapy*
  • Coronary Disease / physiopathology
  • Coronary Disease / prevention & control*
  • Female
  • Humans
  • Male
  • Risk Factors

Substances

  • Cholesterol, LDL
  • Cholesterol